Zhejiang Huahai Pharmaceutical's (SHA:600521) net profit attributable to shareholders in the first half fell 45% to 409.5 million yuan from 748.6 million yuan a year earlier, according to a Shanghai bourse filing on Tuesday.
The Chinese pharmaceutical company's earnings per share dropped 46% year on year to 0.28 yuan from 0.52 yuan.
Operating revenue declined 12% to 4.52 billion yuan from 5.13 billion yuan in the prior year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments